Table 1 Clinical and Conventional Imaging Characteristics
| Â | Normal Diastolic Filling (n = 40) | Grade 1 Diastolic Dysfunction (n = 21) | Grade 2 Diastolic Dysfunction (n = 45) | Grade 3 Diastolic Dysfunction (n = 9) | P |
|---|---|---|---|---|---|
CLINICAL | Â | Â | Â | Â | Â |
Age (year) | 50 ± 10 | 62 ± 7 | 61 ± 14 | 52 ± 12 | < 0.001 |
Male gender | 90% (36) | 86% (18) | 71% (32) | 100% (9) | 0.05* |
Atherosclerosis Risk Factors | Â | Â | Â | Â | Â |
   Hypertension | 28% (11) | 43% (9) | 62% (28) | 22% (2) | 0.007 |
   Hyperlipidemia | 33% (13) | 38% (8) | 60% (27) | 56% (5) | 0.06* |
   Diabetes Mellitus | 18% (7) | 10% (2) | 27% (12) | 22% (2) | 0.41 |
   Tobacco Use | 40% (16) | 24% (5) | 40% (18) | 33% (3) | 0.58 |
   Family History | 38% (15) | 24% (5) | 18% (8) | 22% (3) | 0.22 |
Coronary Artery Disease History | Â | Â | Â | Â | Â |
   Prior Myocardial Infarction | 3% (1) | 14% (3) | 4% (2) | 0% (-) | 0.20 |
   Prior Coronary Revascularization | 5% (2) | 19% (4) | 11% (5) | 11% (1) | 0.40 |
Cardiovascular Medications | Â | Â | Â | Â | Â |
   Beta-blocker | 100% (40) | 100% (21) | 98% (44) | 100% (9) | 0.67 |
   ACE Inhibitor/ARB | 73% (29) | 62% (13) | 82% (37) | 67% (6) | 0.33 |
   HMG-CoA Reductase Inhibitor | 98% (39) | 100% (21) | 93% (42) | 100% (9) | .47 |
   Aspirin | 100% (40) | 100% (21) | 100% (45) | 100% (9) | - |
   Thienopyridines | 98% (39) | 95% (20) | 93% (42) | 100% (9) | 0.72 |
Infarct Related Artery | Â | Â | Â | Â | Â |
   Left Anterior Descending | 58% (23) | 62% (13) | 64% (29) | 78% (7) | 0.71 |
   Right Coronary | 33% (13) | 24% (5) | 29% (13) | 11% (1) | 0.60 |
   Left Circumflex | 10% (4) | 14% (3) | 7% (3) | 0% (-) | 0.57 |
Revascularization Strategy | Â | Â | Â | Â | Â |
   Primary Percutaneous Intervention | 73% (29) | 62% (13) | 67% (30) | 56% (5) | 0.72 |
   Primary Thrombolysis | 25% (10) | 43% (9) | 27% (12) | 44% (4) | 0.36 |
ECHOCARDIOGRAPHY | Â | Â | Â | Â | Â |
LV Morphology/Systolic Function | Â | Â | Â | Â | Â |
   Ejection Fraction (%) | 50 ± 8 | 50 ± 11 | 48 ± 12 | 32 ± 15 | < 0.001 |
   Wall Motion Score | 13 ± 10 | 14 ± 11 | 15 ± 12 | 33 ± 14 | < 0.001 |
   End-diastolic diameter (cm) | 5.6 ± 0.5 | 5.8 ± 0.5 | 5.6 ± 0.5 | 6.2 ± 0.4 | 0.01 |
   End-systolic diameter (cm) | 4.1 ± 0.5 | 4.3 ± 0.6 | 4.2 ± 0.6 | 5.1 ± 0.7 | < 0.001 |
   Relative Wall Thickness (g/m2) | .030 ± 0.04 | 0.29 ± 0.03 | 0.31 ± 0.04 | 0.25 ± 0.04 | 0.005 |
   Myocardial Mass (g/m2) | 92 ± 15 | 97 ± 14 | 96 ± 15 | 92 ± 16 | 0.56 |
Left Atrial Diameter (cm) | 3.8 ± 0.5 | 3.9 ± 0.6 | 4.0 ± 0.5 | 4.4 ± 0.4 | 0.005 |
CARDIOVASCULAR MAGNETIC RESONANCE | Â | Â | Â | Â | Â |
LV Morphology/Systolic Function | Â | Â | Â | Â | Â |
   Ejection fraction (%) | 57 ± 8 | 55 ± 9 | 54 ± 12 | 41 ± 10 | 0.001 |
   Wall motion Score | 11 ± 9 | 14 ± 7 | 15 ± 10 | 29 ± 12 | < 0.001 |
   End-diastolic volume (ml) | 151 ± 34 | 141 ± 32 | 149 ± 45 | 220 ± 49 | < 0.001 |
   End-systolic volume (ml) | 66 ± 24 | 66 ± 26 | 70 ± 36 | 133 ± 49 | < 0.001 |
   Myocardial Mass (g/m2) | 67 ± 12 | 71 ± 14 | 72 ± 17 | 79 ± 20 | 0.15 |
LV Infarct Size (% myocardium) | 14 ± 9 | 16 ± 9 | 17 ± 10 | 27 ± 8 | 0.005 |
Left Atrial Volume (ml) | 80 ± 19 | 77 ± 20 | 95 ± 31 | 115 ± 25 | < 0.001 |